Skip to Content

Intercell obtains results from its first Phase I investigational vaccine study for Streptococcus pneumoniae

» Initial results from a first-in-man Phase I study indicate safety and immunogenicity of the Streptococcus pneumoniae vaccine candidate

Vienna (Austria), February 11, 2010 – Intercell AG (VSE: “ICLL”) today announced results from a Phase I clinical trial investigating the company’s vaccine candidate for the prevention of infections by the bacterium Streptococcus pneumoniae. Intercell’s investigational prophylactic vaccine candidate (IC47) is a recombinant subunit vaccine consisting of three highly conserved proteins of Streptococcus pneumoniae.

In the first-in-man trial, 32 healthy adults were vaccinated with Intercell’s investigational vaccine. Two antigen dosages, with and without addition of aluminum hydroxide, were applied in four different study groups. The initial analysis of the data has indicated a good safety and tolerability of the vaccine candidate, which was confirmed by a Data Safety Monitoring Board. The vaccine was immunogenic, and antigen dose-dependent induction of antibodies was confirmed for all three proteins of the vaccine.

“We are pleased that we have been able to generate first-in-man data for a further vaccine candidate based on antigens discovered through our Antigen Identification Program (AIP®). Subject to clearance with the authorities and our partners, we next intend to initiate clinical development in two target populations – children and the elderly,” stated Thomas Lingelbach, Intercell’s Chief Operating Officer.

About Streptococcus pneumoniae infections Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations for developing pneumococcal infections. Annually, according to the World Health Organization, the bacterium kills up to one million children under the age of five years worldwide. It accounts for many bacterial Meningitis cases in adults, is the most common cause of Pneumonia, and also causes Bacteremia, Meningitis, and Otitis media in young children.

About Intercell’s Streptococcus pneumoniae vaccine The Company’s vaccine candidate is a recombinant subunit vaccine consisting of three conserved surface proteins from Streptococcus pneumoniae. Two of these proteins were discovered using Intercell’s proprietary Antigen Identification Program (AIP®), while the third was in-licensed from the U.S. Centers for Disease Control and Prevention (CDC). The development of Intercell’s vaccine to prevent pneumococcal disease is supported by PATH, an international global health non-profit organization.

About Intercell AG Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell’s vaccine to prevent Japanese Encephalitis is the Company’s first product on the market. The Company’s technology platforms include an antigen?discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including GSK, Novartis, Merck & Co., Inc., Sanofi Pasteur, and Wyeth. The Company’s pipeline of investigational products includes a Travelers’ Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a Vaccine Enhancement Patch to prevent Pandemic Influenza in combination with an injected vaccine (Phase II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, three other products focused on infectious diseases are in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol “ICLL” (U.S. level one ADR symbol “INRLY”).

For more information, please visit:<>

Contact Intercell AG Lucia Malfent Global Head Corporate Communications Campus Vienna Biocenter 3, A-1030 Vienna P: +43-1-20620-1303 Mail to:

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


Sarah Decottegnie Senior Consultant Capital MS&L 81 Whitfield Street London W1T 4HG t. +44 (0) 20 7307 5330 f. +44 (0) 20 7307 5331


Posted: February 2010